Table 1.
Basic characteristics of the 740 study participants.
| ROS/MAP | |
|---|---|
| Age at death | |
| Mean±SD | 88.0±6.7 |
| Range | 66-108 |
| Male, n (%) | 269 (36.4) |
| Amyloid load (%) (mean± SD ) | 3.5±3.7 |
| Tangles density (mm2) (mean± SD ) | 6.4±8.1 |
| Macroscopic infarct, n (%) | 263 (35.5) |
| Microinfarct, n (%) | 206 (27.8) |
| Neocortical Lewy bodies, n (%) | 75 (10.1) |
| Hippocampal sclerosis, n (%) | 55 (7.4) |
| APOE genotype, n (%)* | |
| ε2ε2 | 6 (0.81) |
| ε2ε3 | 100 (13.51) |
| ε2ε4 | 17 (2.30) |
| ε3ε3 | 433 (58.51) |
| ε3ε4 | 168 (22.70) |
| ε4ε4 | 9 (1.22) |
| CERAD neuritic plaque score, n (%) | |
| Definite AD | 224 (30.27) |
| Probable AD | 247 (33.38) |
| Possible AD | 78 (10.54) |
| No AD | 191 (25.81) |
| Braak score, n (%) | |
| 0 | 9 (1.22) |
| I | 63 (8.51) |
| II | 79 (10.68) |
| III | 220 (29.73) |
| IV | 204 (27.57) |
| V | 158 (21.35) |
| VI | 7 (0.95) |
| NIA-Reagan, n (%) | |
| High likelihood of AD | 128 (17.30) |
| Intermediate Likelihood of AD | 319 (43.11) |
| Low Likelihood of AD | 285 (38.51) |
| No AD | 8 (1.08) |
ROS, the Religious Order Study; MAP, the Memory and Aging Project; APOE, Apolipoprotein E; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; NIA, National Institute on Aging.
APOE genotype is available for 733/740 subjects.
CERAD neuritic plaque score is a semiquantitative measure of neuritic plaques (Mirra, S.S., M.N. Hart, and R.D. Terry, Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med, 1993. 117(2): p. 132-44)
Braak score is semiquantitative measure of neurofibrillary tangles (Braak, H. and E. Braak, Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol, 1991. 82(4): p. 239-59)
NIA-Reagan diagnosis of AD (Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging, 1997. 18(4 Suppl): p. S1-2)